Findings

What do systematic reviews say?

46 questions · 46 findings · 4 reviews

No studies found 2 · 4.3%GRADE not reported 0 · 0%Very low 10 · 21.7%Low 10 · 21.7%Moderate 12 · 26.1%High 12 · 26.1%

Microfilaraemia (mf) prevalence · people with lymphatic filariasis or communities where lymphatic filariasis is endemic

The intervention showed no clear difference in microfilaraemia (mf) prevalence (high certainty).

1 finding from 1 review

Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis 2019 · Cochrane Headline outcomes only
RR 0.98 [0.81, 1.19]
4 studies · 1406 participants
High

Mf density · people with lymphatic filariasis or communities where lymphatic filariasis is endemic

1 finding from 1 review

Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis 2019 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 285 participants
Very low

Cure overall negative parasitological test · patients with treating strongyloides infection

The intervention probably leads to higher cure overall negative parasitological test (moderate certainty).

1 finding from 1 review

Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection 2016 · Cochrane Headline outcomes only
RR 1.79 [1.55, 2.08]
4 studies · 478 participants
Moderate

Adverse events report of adverse events · patients with treating strongyloides infection

The intervention showed no clear difference in adverse events report of adverse events (low certainty).

1 finding from 1 review

Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection 2016 · Cochrane Headline outcomes only
RR 0.8 [0.59, 1.09]
4 studies · 518 participants
Low

Cure overall negative parasitological test · patients with treating strongyloides infection

The intervention showed no clear difference in cure overall negative parasitological test (low certainty).

1 finding from 1 review

Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection 2016 · Cochrane Headline outcomes only
RR 1.07 [0.96, 1.2]
3 studies · 467 participants
Low

Adverse events report of adverse events · patients with treating strongyloides infection

The intervention probably leads to lower adverse events report of adverse events (moderate certainty).

1 finding from 1 review

Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection 2016 · Cochrane Headline outcomes only
RR 0.31 [0.2, 0.5]
3 studies · 507 participants
Moderate